Primary lateral sclerosis: predicting functional outcome
- PMID: 22957717
- DOI: 10.3109/17482968.2012.719237
Primary lateral sclerosis: predicting functional outcome
Abstract
Our objective was to investigate functional outcome in primary lateral sclerosis (PLS). We followed a group of 24 patients with PLS. Clinical (ALSFRS), respiratory, and neurophysiological (electromyography and transcranial magnetic stimulation) evaluations were performed at entry and regularly over the follow-up period. The time taken for a greater than 10% decrease in ALSFRS compared to the first assessment was defined as the dichotomous outcome; prognostic factors were evaluated using the Cox proportional hazard model. Results demonstrated that the median age at symptom onset was 54 years (range 28-75 years). In 46% symptoms began in the lower limbs, in 21% in the upper limbs and in 33% in bulbar muscles. The median symptom duration at first visit was 3.1 years (range 0.9-11.7 years). At last follow-up the median disease duration was 9.9 years (range 4.2-17.6 years). The median follow-up time was 4.6 years (range 2.1-11 years). We excluded from final analysis three patients with positive family history. Older age at onset (p = 0.019) was related to more rapid functional impairment; gender, forced vital capacity, region of onset and neurophysiological changes did not predict outcome. In conclusion, age is the most critical prognostic factor for functional outcome in PLS.
Similar articles
-
Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS.Neurology. 2009 Jun 2;72(22):1948-52. doi: 10.1212/WNL.0b013e3181a8269b. Neurology. 2009. PMID: 19487653
-
Differentiation between primary lateral sclerosis and amyotrophic lateral sclerosis: examination of symptoms and signs at disease onset and during follow-up.Arch Neurol. 2007 Feb;64(2):232-6. doi: 10.1001/archneur.64.2.232. Arch Neurol. 2007. PMID: 17296839
-
The natural history of primary lateral sclerosis.Neurology. 2006 Mar 14;66(5):647-53. doi: 10.1212/01.wnl.0000200962.94777.71. Neurology. 2006. PMID: 16534101
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
-
[Chronic progressive spinobulbar spasticity (primary lateral sclerosis)].Fortschr Neurol Psychiatr. 1996 May;64(5):192-203. doi: 10.1055/s-2007-996385. Fortschr Neurol Psychiatr. 1996. PMID: 8675141 Review. German.
Cited by
-
Frontotemporal Pathology in Motor Neuron Disease Phenotypes: Insights From Neuroimaging.Front Neurol. 2021 Aug 16;12:723450. doi: 10.3389/fneur.2021.723450. eCollection 2021. Front Neurol. 2021. PMID: 34484106 Free PMC article. Review.
-
The clinical and radiological profile of primary lateral sclerosis: a population-based study.J Neurol. 2019 Nov;266(11):2718-2733. doi: 10.1007/s00415-019-09473-z. Epub 2019 Jul 19. J Neurol. 2019. PMID: 31325016
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
